Neuroendocrine tumours trials in France

In France 40 Also abroad 244

40 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Where
Le Kremlin-Bicêtre, Lyon, Marseille, Paris, Strasbourg, Villejuif
Age
12 years and over
People
355 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00
Phase 3Taking people
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Where
Clichy, Dijon, Lyon Cedex 03, Marseille, Pessac, Rennes Cedex, Toulouse Cedex 9, Villejuif
Age
18 years and over
People
390 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07544654 · EU 2025-523869-22-00
Phase 2/3Taking people
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Where
Caen, Clichy, Lille, Lyon, Marseille, Montpellier, Nantes, Rennes, Strasbourg, Toulouse, Villejuif
Age
18 years and over
People
440 worldwide
Run by
Exelixis
See details and how to joinNCT06943755 · EU 2025-521043-20-00
No phaseTaking people
Multicenter Study for External Validation of the TB-NET Score
Where
Clichy
Age
18 years and over
People
400 worldwide
Run by
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
See details and how to joinNCT07903532
Phase 1/2Not yet taking people in France
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
Where
Lyon, Marseille, Villejuif
Age
18 years and over
People
60 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07707895 · EU 2026-525634-27-00
No phaseNot yet taking people in France
Real World Positioning of Tyrosine Kinase Inhibitors (TKIs) Within Systemic Treatment Strategies for Advanced Neuroendocrine Tumors (NETs)
Where
Angers, Caen, Clichy, Dijon, La Tronche, Lille, Lyon, Nantes, Paris, Pessac, Poitiers, Reims, Strasbourg, Tours, Villejuif
Age
18 years and over
People
100
Run by
Hospices Civils de Lyon
See details and how to joinNCT07890012
Phase 3Taking people
A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
Where
Angers, Limoges Cedex I, Strasbourg Cedex 2, Toulouse Cedex 9, Villejuif
Age
18 years and over
People
134 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to join2025-524160-38-00 · EU 2025-524160-38-00
Phase 1Taking people
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Where
Lyon, Marseille, Toulouse Cedex 9
Age
18 years to 100 years
People
116 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00
Phase 3Taking people
Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors
Where
Caen, Clichy, Dijon, Lille, Lyon, Marseille, Paris, Rennes, Villejuif
Age
18 years and over
People
166 worldwide
Run by
Grupo Espanol de Tumores Neuroendocrinos
See details and how to joinNCT06878664 · EU 2024-517921-14-00
No phaseTaking people
Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department
Where
Bordeaux, Marseille, Montpellier, Toulouse
Age
18 years and over
People
350
Run by
Institut du Cancer de Montpellier - Val d'Aurelle
See details and how to joinNCT04104529
Phase 3Taking people
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Where
Bordeaux, Bron, Clichy, Lyon Cedex 03, Marseille, Montpellier Cedex 5, Nantes, Pessac, Pierre-Bénite, Talence, Toulouse
Age
12 years to 100 years
People
240 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06784752 · EU 2024-518325-15-00
Phase 2Taking people
FIRST-NEC - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab (MEDI 4736) with etoposide and platinum as first line treatment in patients with large-cell neuroendocrine carcinomas (LCNECs) of the lung.
Where
Aix En Provence, Amiens Cedex 1, Brest Cedex 2, Caen Cedex 5, Créteil, Grenoble Cedex 9, Lille, Limoges Cedex 1, Lorient, Lyon, Lyon Cedex 02, Marseille, Meaux, Mulhouse, Nice, Paris, Paris Cedex 20, Pringy Cedex, Quimper Cedex, Rennes, Strasbourg, Strasbourg Cedex, Toulon Cedex 9, Villefranche Sur Saone Cedex
Age
18 years and over
People
80
Run by
Centre Leon Berard
See details and how to join2023-506590-35-00 · EU 2023-506590-35-00
No phaseTaking people
Superb Microvascular Imaging (SMI) and Two-Dimensional Endoscopic Ultrasound Guided Shear Wave Elastography (2D-SWE-EUS) in Differential Diagnosis of Pancreatic Adenocarcinoma (PA) From Other Pancreatic Solid Lesions (PSLs) and Pancreatic neuroendocrinE Tumors (pNETs) Malignancy
Where
Lyon
Age
18 years and over
People
150
Run by
GCS Ramsay Santé pour l'Enseignement et la Recherche
See details and how to joinNCT07274657
Phase 3Taking people
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
Where
Creteil Cedex, Lyon, Marseille, Paris, Rouen Cedex, Saint-Herblain, Toulon Cedex 9, Toulouse
Age
18 years and over
People
156 worldwide
Run by
Amgen Inc.
See details and how to join2024-520050-38-00 · EU 2024-520050-38-00
No phaseTaking people
TARGETed Therapy Drug MONITOring in DIGestive Oncology
Where
Amiens, Auxerre, Avignon, Bayeux, Clermont-Ferrand, Clichy, Dijon, Évreux, Lille, Lyon, Marseille, Nancy, Nantes, Nice, Paris, Plérin, Poitiers, Reims, Rennes, Rouen, St-Malo, Strasbourg, Tours, Villejuif
Age
18 years and over
People
330
Run by
UNICANCER
See details and how to joinNCT05443087
Phase 2Taking people
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Where
Créteil, Marseille, Paris, Strasbourg Cedex, Villejuif
Age
18 years and over
People
204 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT05882058 · EU 2023-504247-13-00
No phaseTaking people
Evaluation of the Inflammation-based Index as a Predictive Marker of Clinical and Radiological Response in Patients Treated With Lu-177 Oxodotreotide for Intestinal Neuroendocrine Tumour
Where
Angers, Bordeaux, Caen, Lille, Lyon, Marseille, Montpellier, Nantes, Poitiers, Toulouse
Age
18 years and over
People
150
Run by
Institut Claudius Regaud
See details and how to joinNCT06876532
Phase 1/2Taking people
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Where
Marseille, Toulouse Cedex 9, Villejuif
Age
18 years and over
People
262 worldwide
Run by
IDEAYA Biosciences
See details and how to joinNCT07174583 · EU 2025-523438-24-00
Phase 2Taking people
Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET
Where
Angers, Bordeaux, Brest, Caen Cedex 5, Chambéry, Clermont-Ferrand, Clichy, Dijon, Grenoble Cedex 9, Lille Cedex, Lyon, Lyon Cedex 02, Marseille, Montpellier Cedex 5, Nantes, Nice Cedex 2, Paris, Paris Cedex 13, Pessac, Rouen, Rouen Cedex, St Etienne Cedex 2, St Herblain, Strasbourg Cedex, Toulouse, Vandoeuvre Les Nancy Cedex, Villejuif
Age
18 years and over
People
146
Run by
Institut du Cancer de Montpellier - Val d'Aurelle
See details and how to joinNCT04954820 · EU 2024-511001-28-00
No phaseTaking people
Study of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients With an MEN1 Mutation
Where
Dijon
Age
18 years to 60 years
People
297
Run by
Centre Hospitalier Universitaire Dijon
See details and how to joinNCT06430021
Phase 3Not yet taking people in France
Adjuvant Trial in Pancreatic Neuroendocrine Tumors
Where
Villejuif
Age
18 years and over
People
300
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07591493
Phase 1/2Taking people
Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN
Where
Clichy, Nantes Cedex 1
Age
18 years and over
People
60
Run by
Nantes University Hospital
See details and how to joinNCT06735560 · EU 2023-508567-75-00
Phase 3Taking people
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Where
Bourdeaux, Dijon, Lille, Lyon, Marseille, Montpellier, Nantes, Paris
Age
18 years and over
People
170 worldwide
Run by
Grupo Espanol de Tumores Neuroendocrinos
See details and how to joinNCT05918302 · EU 2022-502154-13-00
Phase 2Taking people
Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
Where
Amiens, Caen, Lille
Age
18 years and over
People
88
Run by
Centre Oscar Lambret
See details and how to joinNCT05500391
No phaseNot yet taking people in France
Survival Without Persistent Limiting Toxicity: Real Life Prospective Cohort of Advanced Neuroendocrine Tumor
Where
Caen, Clermont-Ferrand, Clichy, Dijon, Lille, Lyon, Marseille, Paris, Poitiers, Reims, Rennes, Strasbourg, Toulouse, Tours
Age
18 years and over
People
1,100
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07471425